Salarius to Offer 1.96M Shares, Warrants for Decoy Merger

TL;DR

**DCOY is making a highly dilutive move to acquire Decoy, and existing shareholders are getting the short end of the stick with only 14.8% ownership post-merger.**

AI Summary

Salarius Pharmaceuticals, Inc. (DCOY) filed an S-1/A on October 21, 2025, detailing a proposed offering of 1,960,784 shares of common stock, or pre-funded warrants, along with Series A and Series B Warrants, at an assumed combined public offering price of $4.08 per share. This offering is crucial for the two-step merger with Decoy Therapeutics Inc., initially announced on January 10, 2025, and subsequently amended five times. The merger's first step, which involves Decoy stockholders receiving Salarius' Series A and Series B Preferred Stock, is conditioned on a Qualified Financing of at least $6.0 million, a condition Salarius has already met. Post-merger, Salarius' legacy stockholders are expected to retain approximately 14.8% ownership, while Decoy stockholders will own about 85.2%. The Preferred Stock's conversion ratio is subject to price protection, potentially increasing the underlying common shares from an initial 1,719,324 to a maximum of 4,814,106 if the offering price falls to $3.75 or lower; at the assumed $4.08, it's 4,424,730 shares. The second step requires Nasdaq's initial listing approval and Salarius stockholder approval for the Preferred Stock conversion, as Nasdaq views the Decoy transaction as a 'Change of Control' under Listing Rule 5110(a).

Why It Matters

This S-1/A filing is critical for investors as it outlines the financing mechanism for Salarius' transformative merger with Decoy Therapeutics, a deal that will significantly dilute existing Salarius shareholders, reducing their ownership to approximately 14.8%. The price protection provisions on the Preferred Stock introduce substantial uncertainty regarding future dilution, with up to 4,814,106 shares potentially issued if the offering price hits the $3.75 floor, impacting per-share value. For employees and customers, the merger signifies a strategic shift, potentially consolidating R&D efforts and market focus in the competitive biopharmaceutical landscape. The successful completion of this financing and merger is essential for the combined entity's continued Nasdaq listing and future operational viability.

Risk Assessment

Risk Level: high — The risk level is high due to significant shareholder dilution, with legacy Salarius stockholders retaining only approximately 14.8% of the combined company. Furthermore, the Preferred Stock issued to Decoy stockholders includes price protection provisions, meaning the number of common shares underlying it could increase from 1,719,324 to a maximum of 4,814,106 if the offering price drops to $3.75 or below, creating substantial uncertainty and potential for further dilution.

Analyst Insight

Investors should carefully evaluate the significant dilution and the potential for further dilution from the Preferred Stock's price protection before considering an investment. Given the 'Change of Control' designation by Nasdaq and the need for future stockholder approval, investors should monitor the progress of the initial listing application and the stockholder meeting closely, as these are critical hurdles for the merger's full completion.

Key Numbers

• $4.08 — Assumed Public Offering Price (Closing price of Salarius' common stock on Nasdaq on October 10, 2025, used for offering calculations.)
• 1,960,784 — Shares Offered (Number of common stock shares or pre-funded warrants being offered.)
• $6.0 million — Qualified Financing Minimum (Minimum proceeds required for the Merger Closing, which Salarius has already satisfied.)
• 14.8% — Legacy Salarius Ownership (Percentage of Salarius retained by legacy stockholders post-merger, before this offering's dilutive effects.)
• 85.2% — Decoy Stockholder Ownership (Percentage of Salarius owned by Decoy stockholders post-merger, before this offering's dilutive effects.)
• 1,719,324 — Initial Preferred Stock Underlying Shares (Initial number of common stock shares underlying Series A and B Preferred Stock at Merger Closing.)
• 4,814,106 — Maximum Preferred Stock Underlying Shares (Maximum number of common stock shares underlying Preferred Stock if offering price is $3.75 or lower due to price protection.)
• 4,424,730 — Expected Preferred Stock Underlying Shares (Number of common stock shares underlying Preferred Stock based on the assumed $4.08 offering price.)
• 5 — Number of Merger Agreement Amendments (The Merger Agreement with Decoy Therapeutics has been amended five times since January 10, 2025.)
• 45 — Underwriters' Option Days (Number of days the underwriters have an option to purchase additional shares and/or warrants.)

Key Players & Entities

• Salarius Pharmaceuticals, Inc. (company) — Registrant and acquiring company
• Decoy Therapeutics Inc. (company) — Target company in the merger
• Mark J. Rosenblum (person) — Acting Chief Executive Officer, Executive Vice President and Chief Financial Officer of Salarius
• The Nasdaq Capital Market (regulator) — Listing exchange for Salarius common stock and requiring initial listing criteria for combined entity
• $4.08 (dollar_amount) — Assumed combined public offering price per share of common stock and accompanying common warrants
• $6.0 million (dollar_amount) — Minimum proceeds required for Qualified Financing, a condition for the Merger Closing
• 14.8% (percentage) — Approximate ownership retained by Salarius' legacy stockholders post-merger
• 85.2% (percentage) — Approximate ownership by Decoy stockholders post-merger
• $3.75 (dollar_amount) — Floor Price for the Preferred Stock's conversion ratio adjustment
• Ladenburg Thalmann (company) — Underwriter for the offering

FAQ

Risk Factors

• Reliance on Future Financing [high — financial]: The company's ability to continue as a going concern is highly dependent on its ability to secure additional funding through equity or debt financings. The current S-1/A filing is part of an effort to raise capital, but there is no guarantee of success. Failure to obtain necessary funding could materially impact operations.
• FDA Approval Uncertainty [high — regulatory]: Salarius' product candidates are in early-stage development, and their success is contingent upon successful clinical trials and subsequent FDA approval. The development process is lengthy, expensive, and uncertain, with no assurance that any drug candidate will receive regulatory approval.
• Dependence on Key Personnel [medium — operational]: The company's success relies heavily on its management team and scientific advisors. The loss of key personnel could disrupt research and development efforts and strategic planning, potentially hindering progress.
• Competitive Landscape [medium — market]: The pharmaceutical industry is highly competitive, with numerous companies developing therapies for similar indications. Salarius faces competition from established pharmaceutical companies and emerging biotechnology firms, which could impact market share and pricing power.
• Intellectual Property Risks [medium — legal]: The company's ability to protect its intellectual property (IP) is critical. Challenges to patent validity or infringement claims could result in costly litigation and diminish the company's competitive advantage.
• Dilution from Future Offerings [high — financial]: The current offering, and any future equity financings, will likely result in significant dilution to existing stockholders. The proposed merger structure already indicates substantial ownership by Decoy stockholders (85.2%), and further capital raises will exacerbate this dilution.
• Nasdaq Listing Requirements [high — regulatory]: The proposed merger is contingent on Nasdaq's initial listing approval, which views the Decoy transaction as a 'Change of Control' under Listing Rule 5110(a). Failure to meet Nasdaq's listing standards could prevent the transaction from closing.

Industry Context

Salarius operates in the highly competitive biotechnology sector, focusing on developing novel cancer therapies. The industry is characterized by long development cycles, significant R&D investment, and high regulatory hurdles. Success hinges on scientific innovation, clinical trial outcomes, and securing substantial funding to navigate these challenges.

Regulatory Implications

The company faces significant regulatory risks related to FDA approval for its drug candidates. Furthermore, the proposed merger requires Nasdaq's approval, as the transaction is classified as a 'Change of Control,' necessitating adherence to specific listing rules.

What Investors Should Do

1. Review the detailed terms of the proposed offering and merger agreement.
2. Assess the company's cash runway and future financing needs.
3. Evaluate the clinical development status and regulatory pathway for Salarius' drug candidates.

Key Dates

• 2025-01-10: Initial Merger Announcement — Marks the beginning of the proposed two-step merger between Salarius Pharmaceuticals and Decoy Therapeutics Inc.
• 2025-10-21: S-1/A Filing — Details the proposed offering of common stock and warrants, crucial for the merger's first step and capital raise.

Glossary

S-1/A

An amendment to a registration statement filed with the SEC, providing updated or additional information about a securities offering. (This filing contains the detailed terms of the proposed stock and warrant offering and the merger.)

Pre-funded Warrants

A type of warrant that allows the holder to purchase a share of common stock at a nominal exercise price, often used in offerings to allow investors to participate in the offering while avoiding immediate dilution from a full share purchase. (These are being offered alongside common stock, providing an alternative for investors.)

Qualified Financing

A financing round that meets specific criteria, such as a minimum amount raised, as defined in a merger or acquisition agreement. (This was a condition for the first step of the merger, which Salarius has satisfied ($6.0 million minimum).)

Price Protection

A feature in warrant or preferred stock terms that adjusts the conversion price or exercise price if the company's stock price falls below a certain level. (This feature could increase the number of underlying common shares for the Preferred Stock if the offering price is $3.75 or lower.)

Change of Control

A transaction or event that results in a change in the majority ownership or effective control of a company. (Nasdaq considers the Decoy transaction a 'Change of Control,' requiring specific approvals for listing.)

Year-Over-Year Comparison

As this is an S-1/A filing detailing a proposed offering and merger, a direct comparison of key financial metrics like revenue, net income, or margins to a previous year's filing is not applicable. The filing primarily focuses on the terms of the current transaction, the proposed capital raise, and the implications of the merger with Decoy Therapeutics, including significant ownership shifts and potential dilution.

Key Financial Figures

• $0.0001 — 4 shares of its common stock, par value $0.0001 per share (the "common stock"), Series
• $4.08 — sumed combined public offering price of $4.08 per share of common stock and accompany
• $10.50 — y a fraction, the numerator of which is $10.50 (the "Initial Issuance Price") and the
• $3.75 — event will the denominator be less than $3.75 (the "Floor Price"). Accordingly, the n
• $6.0 million — um proceeds from financings of at least $6.0 million (collectively, the "Qualified Financing
• $4 — pon an assumed public offering price of $4.08, the closing price of Salarius' comm

Filing Documents

• flks-20251021.htm (S-1/A) — 1686KB
• exhibit231-sx1a7.htm (EX-23.1) — 2KB
• exhibit232-sx1a7.htm (EX-23.2) — 3KB
• fruciassociateslogoa.jpg (GRAPHIC) — 136KB
• 0001628280-25-045619.txt ( ) — 2211KB
• flks-20251021.xsd (EX-101.SCH) — 2KB
• flks-20251021_lab.xml (EX-101.LAB) — 19KB
• flks-20251021_pre.xml (EX-101.PRE) — 11KB
• flks-20251021_htm.xml (XML) — 2KB

Use of Proceeds

Use of Proceeds 72 Market Price Information 74 Dividend Policy 75 Capitalization 76

Dilution

Dilution 78 Principal Stockholders of Salarius 80 Principal Stockholders of the Combined Company 82

Description of Capital Stock

Description of Capital Stock 84

Description of Securities Salarius is Offering

Description of Securities Salarius is Offering 90 Material U.S Federal Income Tax Consequences 95

Underwriting

Underwriting 103 Legal Matters 108 Experts 108 Where You Can Find More Information 108 Incorporation of Certain Information by Reference 109 Unaudited Pro Forma Consolidated Combined Financial Information 110 References to " Salarius " and " Decoy " in this prospectus refer to Salarius Pharmaceuticals, Inc. and Decoy Therapeutics, Inc., respectively. References to the " combined company " refer to Salarius and its wholly owned subsidiary, Decoy, after the Merger, assuming the Merger is consummated. Except as otherwise noted, references to " we ," " us " or " our " refer to Salarius. References to " First Merger Sub " refer to Decoy Therapeutics MergerSub I, Inc., a newly formed, wholly owned subsidiary of Salarius and references to " Second Merger Sub " refer to Decoy Therapeutics MergerSub II, LLC, a newly formed, wholly owned subsidiary of Salarius. References to the " Merger Agreement " refer to that certain Agreement and Plan of Merger dated as of January 10, 2025, among Salarius, First Merger Sub, Second Merger Sub and Decoy, as amended from time to time. References to the " Merger " refers collectively to the merger of First Merger Sub with and into Decoy, with Decoy surviving as the surviving entity and as a wholly owned subsidiary of Salarius, and the merger of Decoy with and into Second Merger Sub, with Second Merger Sub being the surviving entity and continuing under the name "Decoy Therapeutics, LLC" as a wholly owned subsidiary of Salarius, in each case as contemplated under the Merger Agreement. i ABOUT THIS PROSPECTUS Salarius incorporates by reference important information into this prospectus. You may obtain the information incorporated by reference without charge by following the instructions under "Incorporation of Certain Information by Reference." You should carefully read this prospectus as well as additional information described under "Incorporation of Certain Information by Reference," before deciding to invest in Salar

Forward-looking statements in this prospectus include, but are not limited to, statements about the following

Forward-looking statements in this prospectus include, but are not limited to, statements about the following: the expected benefits of, and potential value created by, the Merger for the securityholders of Salarius and Decoy; the likelihood of the satisfaction of certain conditions to the completion of the Merger, including the conditions related to this offering, whether and when the Merger will be consummated and that Salarius' common stock remains listed on Nasdaq; the effects of the Merger and this offering on the ownership percentages of the Decoy's stockholders and Salarius' stockholders in the combined company; Salarius' expectations regarding the timing of the combined company's ability to satisfy the Nasdaq initial listing standard and obtain stockholder approval for the conversion of the Preferred Stock into common stock in connection with step two of the Decoy transaction; the plans, strategies and objectives of management for future operations, including the execution of integration plans and the anticipated timing of filings, commencement of preclinical studies or clinical trials and release of data from such studies or trials; plans to develop and commercialize additional products candidates including planned preclinical, clinical, regulatory, commercialization and manufacturing activities; the attraction and retention of highly qualified personnel; the ability to protect and enhance the combined company's products and intellectual property; developments and projections relating to the combined company's competitors or industry; the combined company's financial performance; Salarius' or Decoy's relationships and actions with third parties; Salarius' and the combined company's ability to maintain the listing of its shares of common stock on Nasdaq, and the potential liquidity and trading of such shares of common stock; the ability of Salarius and the combined company to successfully manage its cash and cash equivalents and any anticipated

View Full Filing

View this S-1/A filing on SEC EDGAR